Back
46
Also listed as
SNYNF
OTC
Day Range
$44.50
$45.25
52-Week Range
$43.32
$56.93
Volume
3,063,026
50D / 200D Avg
$46.55
/
$48.31
Prev Close
$44.60
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 14.0 | 0.4 |
| P/B | 1.5 | 2.9 |
| ROE % | 10.5 | 3.7 |
| Net Margin % | 16.7 | 3.8 |
| Rev Growth 5Y % | 4.5 | 10.0 |
| D/E | 0.3 | 0.2 |
Key Takeaways
Revenue grew 4.50% annually over 5 years — modest growth
Earnings grew 40.52% over the past year
ROE of 10.50% — decent returns on equity
Net margin of 16.72% shows strong profitability
Debt/Equity of 0.31 — conservative balance sheet
Generating 8.89B in free cash flow
Growth
Revenue Growth (5Y)
4.50%
Revenue (1Y)5.49%
Earnings (1Y)40.52%
FCF Growth (3Y)1.45%
Quality
Return on Equity
10.50%
ROIC5.11%
Net Margin16.72%
Op. Margin13.58%
Safety
Debt / Equity
0.31
Current Ratio1.09
Interest Coverage11.73
Valuation
P/E Ratio
13.96
P/B Ratio1.53
EV/EBITDA19.41
Dividend Yield0.05%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 5.49% | Revenue Growth (3Y) | 5.95% |
| Earnings Growth (1Y) | 40.52% | Earnings Growth (3Y) | 20.29% |
| Revenue Growth (5Y) | 4.50% | Earnings Growth (5Y) | 5.85% |
| Profitability | |||
| Revenue (TTM) | 46.72B | Net Income (TTM) | 7.81B |
| ROE | 10.50% | ROA | 6.16% |
| Gross Margin | 72.34% | Operating Margin | 13.58% |
| Net Margin | 16.72% | Free Cash Flow (TTM) | 8.89B |
| ROIC | 5.11% | FCF Growth (3Y) | 1.45% |
| Safety | |||
| Debt / Equity | 0.31 | Current Ratio | 1.09 |
| Interest Coverage | 11.73 | Dividend Yield | 0.05% |
| Valuation | |||
| P/E Ratio | 13.96 | P/B Ratio | 1.53 |
| P/S Ratio | 2.33 | PEG Ratio | -1.66 |
| EV/EBITDA | 19.41 | Dividend Yield | 0.05% |
| Market Cap | 109.03B | Enterprise Value | 123.16B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 46.72B | 44.29B | 41.62B | 40.56B | 39.18B |
| Net Income | 7.81B | 5.56B | 5.40B | 8.37B | 6.22B |
| EPS (Diluted) | 2.03 | 2.19 | 2.15 | 3.18 | 2.49 |
| Gross Profit | 33.79B | 31.08B | 28.99B | 28.68B | 26.92B |
| Operating Income | 6.34B | 7.25B | 6.96B | 10.16B | 8.13B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 126.81B | 132.80B | 126.46B | 126.72B | 120.24B |
| Total Liabilities | 55.10B | 54.94B | 52.11B | 51.57B | 51.21B |
| Shareholders' Equity | 71.38B | 77.51B | 74.04B | 74.78B | 68.68B |
| Total Debt | 21.79B | 17.91B | 18.70B | 21.21B | 22.41B |
| Cash & Equivalents | 7.66B | 7.44B | 8.71B | 12.74B | 10.10B |
| Current Assets | 30.95B | 42.59B | 30.66B | 34.03B | 30.56B |
| Current Liabilities | 28.35B | 29.16B | 24.19B | 23.96B | 21.30B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#501 of 1024
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026